Proteomic analysis of cerebrospinal fluid in patients with herpes zoster

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200057935

Enrollment

Unknown

Registered

2022-03-22

Start date

2022-04-01

Completion date

Unknown

Last updated

2023-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster

Interventions

Herpes zoster group:

Control group:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Herpes zoster group: (1) There was obvious neuralgia, may be accompanied by local lymph node enlargement; (2) Clusters of blisters along the nerve in a zonal distribution; (3) The dose of pregabalin was 150 mg Bid; (4) Surgical indications for spinal cord electrostimulation electrode implantation; 2. Control group: Patients requiring lumbar anesthesia puncture for surgical treatment.

Exclusion criteria

Exclusion criteria: 1. Herpes zoster group: patients with other diseases of the nervous system, blood diseases, tumors, bleeding tendency, and cardiac pacemaker installation; 2. Control group: patients with chronic pain or pregnant women.

Design outcomes

Primary

Measure	Time frame
proteomics;	—

Countries

China

Contacts

Public ContactYaping Wang

The Second Xiangya Hospital of Central South University

wangyaping6568@126.com+86 13607314476

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026